carmot glp 1 Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare Carmot's CT-996 GLP-1 candidate supports

While patients living with chronic life-threatening conditions like Type 2 diabetes may accept these risks, people using GLP-1 drugs for less life-threatening and severe purposes like obesity may be less forgiving if the side effects outweigh the perceived benefits

On a GLP-1

As addiction progresses, wanting increasingly dominates and becomes dissociated from liking.148 The dark side hypothesis of addiction suggests that impulsivity, compulsivity, and negative urgency emerge from stress experienced during withdrawal or the negative affective phase, potentially persisting months post-withdrawal

2 - ( - , , , 3- II III )